National Academy of Medicine

It’s Time to Harmonize Clinical Trial Site Standards

Climbing costs and lengthy time frames of clinical trials are significant bottlenecks in medical product development. Despite the fact that scientifi
Read More

Interventions Aimed at Reducing Antimicrobial Usage and Resistance in Production Animals in Denmark

    Antimicrobial Usage and Interventions: A Brief History from 1950 to the Present Antimicrobials fo
Read More

Alternatives to Antibiotics: Why and How

  The antibiotic resistance problem is caused by the evolution and transfer of genes that confer resistance to medically important antibiotics into human pathoge
Read More

Real-World Evidence to Guide the Approval and Use of New Treatments

Research regarding new treatments (drugs, biological products, and high-risk devices) often begins with a broad assessment of disease
Read More

Disruptive Innovation and Transformation of the Drug Discovery and Development Enterprise

Declining or stagnant research and development (R&D) productivity has led many observers to argue that the
Read More

FDA and the Media: Lessons from Tysabri about Communicating Uncertainty

Despite a rigorous approval process, there is always uncertainty about newly approved drugs: will the benefits observed in initial
Read More